Welcome to the Oltvai Lab

• 1. Nkosi D
  2. Crowe WE
  3. Altman BJ
  4. Oltvai ZN
  5. Giampoli EJ
  6. Velez MJ
  SATB2 is an Emergent Biomarker of Anaplastic Thyroid Carcinoma: A Series with Comprehensive Biomarker and Molecular Studies.; Endocrine pathology. 2024 Nov 05.
• 1. Kohram M
  2. Sanderson AE
  3. Loui A
  4. Thompson PV
  5. Vashistha H
  6. Shomar A
  7. Oltvai ZN
  8. Salman H
  Nonlethal deleterious mutation-induced stress accelerates bacterial aging.; Proceedings of the National Academy of Sciences of the United States of America; Vol 121(20), pp. e2316271121. 2024 May 06.
• 1. George GV
  2. Liu H
  3. Jajosky AN
  4. Oltvai ZN
  Resolving Discrepancies in Idylla BRAF Mutational Assay Results Using Targeted Next-Generation Sequencing.; Genes; Vol 15(5). 2024 Apr 23.
• 1. Irie N
  2. Mizoguchi K
  3. Warita T
  4. Nakano M
  5. Sasaki K
  6. Tashiro J
  7. Osaki T
  8. Ishikawa T
  9. Oltvai ZN
  10. Warita K
  Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines.; Biomedicines; Vol 12(3). 2024 Mar 21.
• 1. Cox AJ
  2. Crowe WE
  3. Yang Q
  4. Zhang B
  5. Oltvai ZN
  6. Liao X
  Clinicopathologic and Molecular Characterization of Anorectal Neuroendocrine Carcinomas Reveals Human Papillomavirus, p53 and c-Myc as Alternative Mechanisms of Carcinogenesis.; Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2023 Jul 28.
• 1. Nkosi D
  2. George GV
  3. Liu H
  4. Buldo M
  5. Velez MJ
  6. Oltvai ZN
  Efficient Lung Cancer Molecular Diagnostics by Combining Next Generation Sequencing with Reflex Idylla Genefusion Assay Testing.; Genes; Vol 14(8). 2023 Jul 28.

April 20, 2021
Study by Zoltan Oltvai Examines Targeted Therapy Resistance in AML

View All News